{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:29:06Z","timestamp":1792114146817,"version":"4.4.0"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU 01.924, TTU 01.709, TTU 01.702, TTU 01.921, TI07.003_Dieck, TI 07.001_Mellinghoff"],"award-info":[{"award-number":["TTU 01.924, TTU 01.709, TTU 01.702, TTU 01.921, TI07.003_Dieck, TI 07.001_Mellinghoff"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008662","name":"Joachim Herz Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["493624519, 407495230"],"award-info":[{"award-number":["493624519, 407495230"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Vaccine platforms such as viral vectors and mRNA can accelerate vaccine development in response to newly emerging pathogens, as demonstrated during the COVID-19 pandemic. However, the differential effects of platform and antigen insert on vaccine immunogenicity remain incompletely understood. Innate immune responses induced by viral vector vaccines are suggested to have an adjuvant effect for subsequent adaptive immunity. Integrating data on both innate and adaptive immunity, systems vaccinology approaches can improve the understanding of vaccine-induced immune mechanisms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Two vaccine candidates against SARS-CoV-2, both based on the viral vector Modified Vaccinia virus Ankara (MVA) and encoding the native (MVA-SARS-2-S) or prefusion-stabilized spike protein (MVA-SARS-2-ST), were evaluated in phase 1 clinical trials (ClinicalTrials.gov: NCT04569383, NCT04895449). Longitudinal dynamics of innate and early adaptive immune responses induced by vaccination in SARS-CoV-2-na\u00efve individuals were analyzed based on transcriptome and flow cytometry data, in comparison to the licensed ChAd and mRNA vaccines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared to MVA-SARS-2-S, MVA-SARS-2-ST (encoding the prefusion-stabilized spike protein) induced a stronger transcriptional activation early after vaccination, as well as higher virus neutralizing antibodies. Positive correlations were observed between innate and adaptive immune responses induced by a second MVA-SARS-2-ST vaccination. MVA-, ChAd- and mRNA-based vaccines induced distinct immune signatures, with the overall strongest transcriptional activation as well as monocyte and circulating T follicular helper (cTFH) cell responses induced by ChAd.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Our findings suggest a potential impact of the spike protein conformation not only on adaptive but also on innate immune responses. As indicated by positive correlations between several immune parameters induced by MVA-SARS-2-ST, the distinct transcriptional activation early after vaccination may be linked to the induction of classical monocytes and activation of cTFH1 cells, which may in turn result in the superior adaptive immunogenicity of MVA-SARS-2-ST, compared to MVA-SARS-2-S. Overall, our data demonstrate that both the vaccine platform and antigen insert can affect innate immune responses and subsequent vaccine immunogenicity in humans.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1500615","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T06:26:43Z","timestamp":1734589603000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["MVA-based SARS-CoV-2 vaccine candidates encoding different spike protein conformations induce distinct early transcriptional responses which may impact subsequent adaptive immunity"],"prefix":"10.3389","volume":"15","author":[{"given":"Ilka","family":"Grewe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Louise","family":"Dieck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Spohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"My Linh","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Kr\u00e4hling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle C.","family":"Mellinghoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Rottstegge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekka","family":"Kraemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asisa","family":"Volz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahita","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Dahlke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie M.","family":"Weskamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marylyn M.","family":"Addo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41563-020-0746-0","article-title":"Next-generation vaccine platforms for COVID-19","volume":"19","author":"van Riel","year":"2020","journal-title":"Nat Mater"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00571-6","article-title":"Mpox neutralising antibodies at 6 months from mpox infection or MVA-BN vaccination: a comparative analysis","volume":"23","author":"Moschetta","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"B4","unstructured":"Imvanex - smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)\n          \n          2022"},{"key":"B5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","article-title":"Modified vaccinia virus ankara: history, value in basic research, and current perspectives for vaccine development","volume":"97","author":"Volz","year":"2017","journal-title":"Adv Virus Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S1473-3099(21)00125-0","article-title":"Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial","volume":"22","author":"Ishola","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B7","unstructured":"Mvabea - Ebola vaccine (MVA-BN-Filo [recombinant])\n          \n          2020"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30248-6","article-title":"Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial","volume":"20","author":"Koch","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4802678","article-title":"The safety, immunogenicity, and optimal dosing of an MVA-based vaccine against MERS coronavirus in healthy adults: A phase 1b, randomised, placebo-controlled, double-blind clinical trial","author":"Raadsen","year":"2024","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI159895","article-title":"Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity","volume":"132","author":"Meyer Zu Natrup","year":"2022","journal-title":"J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41541-023-00801-z","article-title":"MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans","volume":"9","author":"Mayer","year":"2024","journal-title":"NPJ Vaccines"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV\u2013a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd4251","article-title":"Distinct conformational states of SARS-CoV-2 spike protein","volume":"369","author":"Cai","year":"2020","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0403492101","article-title":"Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity","volume":"101","author":"Buchholz","year":"2004","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2026207118","article-title":"Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination","volume":"118","author":"Tscherne","year":"2021","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2010.12.012","article-title":"Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion","volume":"34","author":"Morita","year":"2011","journal-title":"Immunity"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01253-8","article-title":"Targeting T(FH) cells in human diseases and vaccination: rationale and practice","volume":"23","author":"Yu","year":"2022","journal-title":"Nat Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"176ra32","DOI":"10.1126\/scitranslmed.3005191","article-title":"Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination","volume":"5","author":"Bentebibel","year":"2013","journal-title":"Sci Transl Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aag2152","article-title":"Successive annual influenza vaccination induces a recurrent oligoclonotypic memory response in circulating T follicular helper cells","volume":"2","author":"Herati","year":"2017","journal-title":"Sci Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"26494","DOI":"10.1038\/srep26494","article-title":"ICOS(+)PD-1(+)CXCR3(+) T follicular helper cells contribute to the generation of high-avidity antibodies following influenza vaccination","volume":"6","author":"Bentebibel","year":"2016","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"104788","DOI":"10.1016\/j.ebiom.2023.104788","article-title":"Lower magnitude and faster waning of antibody responses to SARS-CoV-2 vaccination in anti-TNF-\u03b1-treated IBD patients are linked to lack of activation and expansion of cTfh1 cells and impaired B memory cell formation","volume":"96","author":"Garner-Spitzer","year":"2023","journal-title":"EBioMedicine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1129","article-title":"Dynamic changes in circulating T follicular helper cell composition predict neutralising antibody responses after yellow fever vaccination","volume":"9","author":"Huber","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"100207","DOI":"10.1016\/j.xcrm.2021.100207","article-title":"Protein\/AS01(B) vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors","volume":"2","author":"Nielsen","year":"2021","journal-title":"Cell Rep Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.v101.6","article-title":"T follicular helper cell responses to SARS-CoV-2 vaccination among healthy and immunocompromised adults","volume":"101","author":"Boyd","year":"2023","journal-title":"Immunol Cell Biol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"102210","DOI":"10.1016\/j.coi.2022.102210","article-title":"Viral vector vaccines","volume":"77","author":"McCann","year":"2022","journal-title":"Curr Opin Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-021-01046-z","article-title":"Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults","volume":"7","author":"Romero-Olmedo","year":"2022","journal-title":"Nat Microbiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"100971","DOI":"10.1016\/j.xcrm.2023.100971","article-title":"A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines","volume":"4","author":"Ryan","year":"2023","journal-title":"Cell Rep Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12916-024-03304-3","article-title":"Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination","volume":"22","author":"Mart\u00edn P\u00e9rez","year":"2024","journal-title":"BMC Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1038\/s41467-023-39292-w","article-title":"Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration","volume":"14","author":"Follmann","year":"2023","journal-title":"Nat Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e1010016","DOI":"10.1371\/journal.ppat.1010016","article-title":"Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials","volume":"17","author":"Fischinger","year":"2021","journal-title":"PloS Pathog"},{"key":"B34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41541-020-00243-x","article-title":"Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses","volume":"5","author":"Bos","year":"2020","journal-title":"NPJ Vaccines"},{"key":"B35","doi-asserted-by":"publisher","first-page":"107882","DOI":"10.1016\/j.isci.2023.107882","article-title":"ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface","volume":"26","author":"Ni","year":"2023","journal-title":"iScience"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.1c00058","article-title":"Assessing antigen structural integrity through glycosylation analysis of the SARS-coV-2 viral spike","volume":"7","author":"Brun","year":"2021","journal-title":"ACS Cent Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2351664","DOI":"10.1080\/21645515.2024.2351664","article-title":"Characterization and immunogenicity assessment of MERS-CoV pre-fusion spike trimeric oligomers as vaccine immunogen","volume":"20","author":"Ahuja","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nri2629","article-title":"Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology","volume":"9","author":"Pulendran","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/imm.2019.156.issue-1","article-title":"Systems vaccinology and big data in the vaccine development chain","volume":"156","author":"Raeven","year":"2019","journal-title":"Immunology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1172\/JCI125372","article-title":"Innate gene signature distinguishes humoral versus cytotoxic responses to influenza vaccination","volume":"129","author":"Gon\u00e7alves","year":"2019","journal-title":"J Clin Invest"},{"key":"B44","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1186\/s12864-021-08061-8","article-title":"Distinct patterns of whole blood transcriptional responses are induced in mice following immunisation with adenoviral and poxviral vector vaccines encoding the same antigen","volume":"22","author":"Sheerin","year":"2021","journal-title":"BMC Genomics"},{"key":"B45","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/ni.2789","article-title":"Molecular signatures of antibody responses derived from a systems biology study of five human vaccines","volume":"15","author":"Li","year":"2014","journal-title":"Nat Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01328-6","article-title":"Transcriptional atlas of the human immune response to 13 vaccines reveals a common predictor of vaccine-induced antibody responses","volume":"23","author":"Hagan","year":"2022","journal-title":"Nat Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41392-023-01408-5","article-title":"Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.3.2134","article-title":"Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo","volume":"181","author":"Appledorn","year":"2008","journal-title":"J Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01597-10","article-title":"Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors","volume":"85","author":"Rhee","year":"2011","journal-title":"J Virol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01884-08","article-title":"Modified vaccinia virus ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression","volume":"83","author":"Lehmann","year":"2009","journal-title":"J Virol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e1000480","DOI":"10.1371\/journal.ppat.1000480","article-title":"Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome","volume":"5","author":"Delaloye","year":"2009","journal-title":"PloS Pathog"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003989","article-title":"Modified vaccinia virus Ankara triggers type I IFN production in murine conventional dendritic cells via a cGAS\/STING-mediated cytosolic DNA-sensing pathway","volume":"10","author":"Dai","year":"2014","journal-title":"PloS Pathog"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01163-9","article-title":"Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine","volume":"23","author":"Li","year":"2022","journal-title":"Nat Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03791-x","article-title":"Systems vaccinology of the BNT162b2 mRNA vaccine in humans","volume":"596","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00925-21","article-title":"Type I interferon promotes humoral immunity in viral vector vaccination","volume":"95","author":"Zhong","year":"2021","journal-title":"J Virol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.586124","article-title":"Immune profiles identification by vaccinomics after MVA immunization in randomized clinical study","volume":"11","author":"Sanchez","year":"2020","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/0165-2427(94)05357-X","article-title":"Interferon induction in peripheral blood mononuclear leukocytes of man and farm animals by poxvirus vector candidates and some poxvirus constructs","volume":"46","author":"B\u00fcttner","year":"1995","journal-title":"Vet Immunol Immunopathol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.645210","article-title":"Vaccine inoculation route modulates early immunity and consequently antigen-specific immune response","volume":"12","author":"Rosenbaum","year":"2021","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"113101","DOI":"10.1016\/j.celrep.2023.113101","article-title":"Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26.ZEBOV\/MVA-BN-Filo","volume":"42","author":"Blengio","year":"2023","journal-title":"Cell Rep"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01524-14","article-title":"Chemokine (C-C Motif) receptor 1 is required for efficient recruitment of neutrophils during respiratory infection with modified vaccinia virus Ankara","volume":"88","author":"Price","year":"2014","journal-title":"J Virol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01190-07","article-title":"Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses","volume":"81","author":"Waibler","year":"2007","journal-title":"J Virol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.0c01537","article-title":"CD209L\/L-SIGN and CD209\/DC-SIGN act as receptors for SARS-coV-2","volume":"7","author":"Amraei","year":"2021","journal-title":"ACS Cent Sci"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/biology10010001","article-title":"C-type lectin CD209L\/L-SIGN and CD209\/DC-SIGN: cell adhesion molecules turned to pathogen recognition receptors","volume":"10","author":"Rahimi","year":"2020","journal-title":"Biol (Basel)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.29.227462","article-title":"SARS-coV-2 spike protein interacts with multiple innate immune receptors","author":"Gao","year":"2020","journal-title":"bioRxiv"},{"key":"B65","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/intimm\/dxp112","article-title":"IL-21 and T follicular helper cells","volume":"22","author":"Spolski","year":"2010","journal-title":"Int Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2011.03487.x","article-title":"The regulation and role of T follicular helper cells in immunity","volume":"134","author":"Deenick","year":"2011","journal-title":"Immunology"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.07.002","article-title":"The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment","volume":"31","author":"Yu","year":"2009","journal-title":"Immunity"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1016\/j.cell.2022.05.022","article-title":"Humoral and cellular immune memory to four COVID-19 vaccines","volume":"185","author":"Zhang","year":"2022","journal-title":"Cell"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/j.immuni.2021.08.001","article-title":"Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination","volume":"54","author":"Painter","year":"2021","journal-title":"Immunity"},{"key":"B70","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2021.12.026","article-title":"SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans","volume":"185","author":"Mudd","year":"2022","journal-title":"Cell"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01145-0","article-title":"Modeling human adaptive immune responses with tonsil organoids","volume":"27","author":"Wagar","year":"2021","journal-title":"Nat Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1016\/j.immuni.2023.06.019","article-title":"Influenza vaccine format mediates distinct cellular and antibody responses in human immune organoids","volume":"56","author":"Kastenschmidt","year":"2023","journal-title":"Immunity"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57111163","article-title":"Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy leading to venous combined micro-macrothrombosis","volume":"57","author":"Chang","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa460","article-title":"Broad antibody and cellular immune response from a phase 2 clinical trial with a novel multivalent poxvirus-based respiratory syncytial virus vaccine","volume":"223","author":"Jordan","year":"2021","journal-title":"J Infect Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1500615\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T06:26:48Z","timestamp":1734589608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1500615\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":74,"alternative-id":["10.3389\/fimmu.2024.1500615"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1500615","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"article-number":"1500615"}}